Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111412 | 0.86 | CYP11B1 (0.51) | CYP11B1CYP11B2HTTSMN1; SMN2MAPT | |
| SCHEMBL3911396 | 0.84 | TP53 (0.53) | CYP11B1CYP11B2HTTSMN1; SMN2MAPT | |
| SCHEMBL3912721 | 0.84 | CYP11B1 (0.54) | CYP11B1CYP11B2SMN1; SMN2LMNAHPGD | |
| SCHEMBL3913908 | 0.84 | IDO1 (0.49) | CYP11B1CYP11B2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3914606 | 0.83 | GRM2 (0.44) | CYP11B1CYP11B2HTTSMN1; SMN2PKM | |
| SCHEMBL2400441 | 0.81 | CYP11B2 (0.56) | CYP11B1CYP11B2MAPTLMNAKDM4E | |
| SCHEMBL3913086 | 0.81 | ABCC8 (0.49) | CYP11B1CYP11B2HTTSMN1; SMN2RAB9A | |
| SCHEMBL3921773 | 0.81 | SMN1; SMN2 (0.50) | CYP11B1CYP11B2HTTSMN1; SMN2KMT2A | |
| SCHEMBL3916349 | 0.80 | PDPK1 (0.40) | — | |
| SCHEMBL3927346 | 0.80 | ALDH1A1 (0.47) | HTTSMN1; SMN2MAPTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | CYP11B1 81/4885CYP11B2 85/4885HTT 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.